Journal of Tumour Research & Reports

Nabil Habib Institute, Sabtieh Sid El Baouchrieh, Lebanon

Biography

Hamid Daaboul Surrey University Hamid Elia Daaboul, MD, PhD is an ASCO active member and researcher in the mode of action of new potential anticancer molecules in the Lebanese American University, Lebanon. He is a practicing Oncologist and also a former head of department of Oncology in Haroun Hospital, Lebanon. He earned his PhD in Oncology from Surrey University, London.

Publications

• Research Article   
  Metastatic breast cancer with a cholesterol derivative (hydroxysterol; 24-ethyl-cholestane-3β,5α,6α-triol) showing high activity and no toxicity
  Author(s): Nabil Habib*, George Hajj, Hamid Daaboul, Abdo Jabbour, Hind Zeitouni and Riad Khalifeh
  
  Breast cancer is the deadliest form of cancer in women worldwide and all current therapies are associated with side effects which may on some occasions be severe without major impact on survival. Oxysterols are oxygenated derivatives of cholesterol. Oxysterols participate in the regulation of cholesterol metabolism, enzyme activity, and signaling pathways such as Hedgehog, Wnt, and MAPK. Some of these derivatives have been found as proinflammatory factors to promote human cancers while others have been found in experimental models to have an anti-proliferative effect. Most of these compounds have been shown to be very toxic. Our new drug (24-ethylcholestane-3β,5α,6α-triol) is the first oxysterol to have reached the clinical level and it has been shown to be very safe. Preliminary results in a variety of tumors have been very encouraging. We performed a phase II trial .. View more»
  

  Abstract PDF